Last A$0.22 AUD
Change Today 0.00 / 0.00%
Volume 521.8K
PBT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
OTC US
Stuttgart
As of 12:10 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PBT) Snapshot

Open
A$0.23
Previous Close
A$0.22
Day High
A$0.23
Day Low
A$0.22
52 Week High
01/31/14 - A$1.37
52 Week Low
05/7/14 - A$0.16
Market Cap
107.6M
Average Volume 10 Days
705.4K
EPS TTM
A$-0.03
Shares Outstanding
488.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRANA BIOTECHNOLOGY LTD (PBT)

Related News

No related news articles were found.

prana biotechnology ltd (PBT) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PBT) Details

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate includes PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds, which support new therapies for the treatment of neurodegenerative disease and other highly prevalent conditions. The company was founded in 1997 and is based in Parkville, Australia.

12 Employees
Last Reported Date: 11/3/14
Founded in 1997

prana biotechnology ltd (PBT) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$444.4K
Chief Operating Officer
Total Annual Compensation: A$324.8K
Company Secretary
Total Annual Compensation: A$50.0K
Compensation as of Fiscal Year 2014.

prana biotechnology ltd (PBT) Key Developments

Prana Biotechnology Limited - Shareholder/Analyst Call

Annual General Meeting

Prana Biotechnology Limited Announces Executive Changes

Prana Biotechnology Limited announced the appointment of Ms. Kathryn Andrews as Chief Financial Officer and Mr. Phillip Hains as Company Secretary. Ms Andrews is a Certified Practicing Accountant and has over 25 years' experience in accounting, commercial management and consulting in various roles. For the past two years Ms. Andrews has held a senor role with The CFO Solution. As principal of The CFO Solution since 1996, Mr. Hains is the Company Secretary for a number of listed companies in the life sciences sector. The appointment follows the resignation of Mr. Richard (Rick) Revelins from the role of CFO and Company Secretary to pursue other commercial interests in the USA. The changes are effective immediately.

Prana Biotechnology Limited announced delayed 20-F filing

On 10/31/2014, Prana Biotechnology Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBT:AU A$0.22 AUD 0.00

PBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBT.
View Industry Companies
 

Industry Analysis

PBT

Industry Average

Valuation PBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.